Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.

Article  PubMed  Google Scholar 

Yanada M, Konuma T, Yamasaki S, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2021;56(5):1126–33.

Article  CAS  PubMed  Google Scholar 

Najima Y. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS. Int J Hematol. 2023;118(2):169–82.

Article  PubMed  Google Scholar 

Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107(2):138–50.

Article  CAS  PubMed  Google Scholar 

Matsuoka K. Post-transplant maintenance therapy: emerging concepts and future perspectives. Jpn J Transplant Cell Ther. 2024;13(1):1–13.

Google Scholar 

Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668–79.

Article  CAS  PubMed  Google Scholar 

Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions–a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant. 2015;21(4):653–60.

Article  CAS  PubMed  Google Scholar 

Rautenberg C, Bergmann A, Pechtel S, et al. Wilm’s tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. Bone Marrow Transplant. 2021;56(2):442–50.

Article  CAS  PubMed  Google Scholar 

Miyawaki S, Emi N, Mitani K, et al. Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Rinsho Ketsueki. 2005;46(12):1279–87.

PubMed  Google Scholar 

Weisser M, Kernb W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19(8):1416–23.

Article  CAS  PubMed  Google Scholar 

Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–201.

Article  CAS  PubMed  Google Scholar 

Polak J, Hajkova H, Haskovec C, et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia – a useful tool for early detection of minimal residual disease. Neoplasma. 2013;60(1):74–82.

Article  CAS  PubMed  Google Scholar 

Pozzi S, Geroldi S, Tedone E, et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol. 2013;160(4):503–9.

Article  PubMed  Google Scholar 

Israyelyan A, Goldstein L, Tsai W, et al. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(1):26–33.

Article  CAS  PubMed  Google Scholar 

Kitamura K, Nishiyama T, Ishiyama K, et al. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol. 2016;103(1):53–62.

Article  CAS  PubMed  Google Scholar 

Mo XD, Qin YZ, Zhang XH, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95(8):1233–40.

Article  CAS  PubMed  Google Scholar 

Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. Cancer Med. 2016;5(2):265–74.

Article  PubMed  Google Scholar 

Duléry R, Nibourel O, Gauthier J, et al. Impact of Wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52(4):539–43.

Article  PubMed  Google Scholar 

Cho BS, Min GJ, Park SS, et al. WT1 measurable residual disease assay in patients with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation: optimal time points, thresholds, and candidates. Biol Blood Marrow Transplant. 2019;25(10):1925–32.

Article  PubMed  Google Scholar 

Lambert J, Lambert J, Thomas X, et al. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv. 2021;5(23):5258–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazzarotto D, Candoni A. The role of Wilms’ tumor gene (WT1) expression as a marker of minimal residual disease in acute myeloid leukemia. J Clin Med. 2022;11(12):3306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arai S, Tachibana T, Izumi A, et al. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Int J Hematol. 2024;120(3):337–46.

Article  CAS  PubMed  Google Scholar 

Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002.

Article  PubMed  Google Scholar 

Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180–9.

Article  CAS  PubMed  Google Scholar 

Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600–11.

Article  CAS  PubMed  Google Scholar 

Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40.

Article  CAS  PubMed  Google Scholar 

Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase3 trial. Lancet Oncol. 2019;20(7):984–97.

Article  CAS  PubMed  Google Scholar 

Terao T, Matsuoka K, Ueda H, et al. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3 mut AML. Blood Adv. 2023;7(5):681–6.

Article  CAS  PubMed  Google Scholar 

Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766–75.

Article  CAS  PubMed  Google Scholar 

de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420–31.

Article  PubMed